Quality of Life After Transcatheter Aortic Valve Replacement

A large database study confirms an improved quality of life for most patients at 1 year but poor outcomes in a substantial minority.

Large randomized trials have demonstrated improvements in survival and quality of life (QOL) in patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Now, investigators have sought to examine QOL at 1 year in a large real-world population drawn from the Society of Thoracic Surgeons and the American College of Cardiology's Transcatheter Valve Therapy (TVT) Registry of U.S. clinical (nonresearch) TAVR patients.

QOL data were based on patients' responses to the Kansas City Cardiomyopathy Questionnaire; its summary scores range from 0 to 100, with higher scores indicating less symptom burden and better QOL. Baseline summary scores were available for 45,564 patients from >400 sites (mean score,…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)